Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
Want to see JP:4534 full AI Analyst Report?
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,859.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥108.04B
Enterprise Value¥92.18B
Total Cash (Recent Filing)¥54.69B
Total Debt (Recent Filing)¥830.00M
Price to Earnings (P/E)14.2
Beta0.64
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)169.96
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.87
Price to Sales (P/S)1.05
P/FCF Ratio-12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low historical leverage and a large equity base give Mochida financial flexibility to fund R&D, support manufacturing or licensing efforts, and absorb cyclical shocks. This conservatism reduces refinancing risk and preserves optionality for strategic investments over the medium term.
Rebounding Revenue And ProfitSustained top-line growth and rising net income through 2026 indicate improving product traction and operational recovery. This strengthens the company's ability to reinvest in pipelines, maintain commercial efforts, and support steady earnings generation over the next several quarters.
Specialized Product Focus And Sales NetworkA focused portfolio in specialty therapy areas plus an established MR-driven domestic sales and distribution capability supports durable prescription demand and effective commercialization of in-licensed products, preserving market position and steady revenue streams over time.
Bears Say
Volatile Cash GenerationLarge swings and intermittent negative OCF/FCF point to working-capital timing or collection issues that undermine the reliability of reported profits converting to cash. This hampers the company's ability to self-fund capex, dividends, or acquisitions without external financing.
Margin And Earnings InconsistencyMaterial margin volatility implies sensitivity to product mix, pricing or reimbursement dynamics. That inconsistency reduces predictability of earnings and complicates multi-quarter planning for R&D, marketing spend, and dividend policy, raising execution risk.
Recent Increase In DebtThe rise in reported debt in 2026, while modest versus equity, increases interest and refinancing exposure. Combined with volatile cash flows, higher debt levels could constrain financial flexibility and raise funding costs when executing strategic initiatives.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2859.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥108.04B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 45 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥44.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥44.05.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥42 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥44.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.399%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---